The capacity of human peripheral blood monocytes, neutrophils, and monocyte-derived macrophages to bind the yeast Cryptococcus neoformans was increased when the phagocytes were cultured on surfaces containing recombinant human mannose-binding protein. In contrast, soluble mannose-binding protein had no effect on cryptococcal binding by phagocytes.
The lymphokine interleukin-2 (IL-2), which is necessary for the generation of an optimal cell-mediated immune response, has recently been shown to have lectinlike properties, with specificity for high-mannose groups. Therefore, the ability of IL-2 to bind to the mannose-rich fungus Candida albicans was examined. Heat-killed fungi preincubated with IL-2 stimulated, in a dose-dependent manner, proliferation of the IL-2-dependent cell line CTLL20. Soluble mannan, which is rich in exposed mannose groups, inhibited binding of IL-2 to C. albicans by approximately 60%, suggesting that the lectinlike properties of IL-2 are partially responsible for its fungal binding capacity. Binding of IL-2 to fungi appeared to be reversible, as C. albicans preincubated with IL-2 stimulated CTLL20 proliferation even when the fungi and cells were separated by an 0.4-,um-pore-size membrane. The lymphoproliferative response of normal human peripheral blood mononuclear cells to C. albicans was augmented when the fungus was preincubated with IL-2. Binding of 1251-IL-2 could not be inhibited by unlabeled IL-2, suggesting the absence of high-affinity receptors on C. albicans for IL-2. While the in vivo relevance remains to be determined, these data demonstrate that IL-2 can bind to C. albicans in vitro and thereby influence the host response to this medically important fungus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.